Equip Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual eating disorder treatment using family-based therapy, San Diego CA, raised $58M+. First at-home model for anorexia and bulimia treatment in the US.
About
Equip Health is a San Diego, California-based virtual care company founded in 2019 that specializes in treating eating disorders including anorexia, bulimia, binge eating disorder, and avoidant restrictive food intake disorder (ARFID). The company has raised over $58 million and has pioneered a virtual delivery model for family-based treatment (FBT), the gold-standard evidence-based therapy for adolescent eating disorders, making intensive evidence-based care accessible outside of residential treatment programs.\n\nEquip's care model assembles a five-person care team for each patient: a therapist, a dietitian, a physician, a family mentor, and a peer mentor — all coordinating through the platform. This team-based virtual approach mirrors the multidisciplinary structure of leading eating disorder treatment centers while eliminating the geographic and financial barriers that prevent most patients from accessing residential care. Sessions are conducted by video with the patient and their family, with meal support and between-session coaching embedded in the program.\n\nThe company distributes its services through insurance coverage, accepting major commercial plans and working to expand Medicaid coverage. Eating disorders carry the highest mortality rate of any psychiatric illness, yet treatment access is severely limited in the United States. Equip's virtual model has treated patients across all 50 states, demonstrating the feasibility of delivering intensive eating disorder care at home and positioning the company as a national provider in a historically fragmented specialty.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.